Healthcare giant Johnson & Johnson (NYSE:JNJ) today topped sales and earnings estimates with its second-quarter financial results, posting sales growth of 19.9% for its pharmaceutical segment compared to the same period last year. The New Brunswick, N.J.-based company reported overall profit growth of 3.1% to $3.95 billion, or $1.45 per share, on sales of $20.83 billion […]
CeQur acquires wearable insulin delivery device
CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction […]
Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity
Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer of more than $2 billion from private equity shop Platinum Equity for its LifeScan blood glucose monitoring business as it moves toward the exit in the diabetes market. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, […]
J&J’s Janssen touts Ph3 data for antidepressant nasal spray
Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression. The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 […]
J&J’s Janssen acquires cancer-killing virus tech
Johnson & Johnson‘s (NYSE:JNJ) Janssen Biotech said today that it agreed to acquire BeneVir Biopharm and its T-Stealth oncolytic virus platform. The privately-held biopharmaceutical company engineers cancer-killing viruses that are designed to infect and destroy cancer cells. Janssen plans to develop BeneVir’s preclinical candidates for the treatment of solid tumor cancers. According to the terms […]
Report: J&J’s Cerenovus to discontinue Codman liver cancer pump
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus is discontinuing production of its Codman pumps designed to deliver targeted chemotherapy to the liver for patients with liver cancer, according to a New York Times report. The devices are designed to be implanted in the abdomen to deliver chemotherapy directly to the liver to treat cancer that has spread […]
Johnson & Johnson’s global pharma sales up 19% in Q1
Johnson & Johnson (NYSE:JNJ) today reported first-quarter sales and earnings results, topping analysts’ expectations on Wall Street. The company’s pharmaceutical business delivered “robust growth,” chairman & CEO Alex Gorsky said in a statement; worldwide global sales grew 19.4% to $9.8 billion for the first quarter compared to same period in 2017. Domestic sales were up […]
Medtech stories we missed this week: April 6, 2018
From CHF Solutions’s distribution deal to Guided Therapeutics’s licensing agreement, here are seven medtech stories we missed this week but throught were still worth mentioning. 1. CHF inks Spanish distribution deal CHF Solutions announced in an April 5 press release that it has signed a distribution agreement with Dimedix Surgical. The distribution agreement will allow […]
Johnson & Johnson moves closer to exiting the diabetes business with $2.1B LifeScan sale
Johnson & Johnson (NYSE:JNJ) took another step toward the exit door for the diabetes business, agreeing to a $2,1 billion offer from private equity shop Platinum Equity for its LifeScan blood glucose monitoring unit. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later […]
Pharma revenue drives Johnson & Johnson’s Q4 beat
Shares in Johnson & Johnson (NYSE:JNJ) fell yesterday after the healthcare giant topped Wall Street’s expectations for fourth-quarter results but missed analysts’ forecast for the full-year. Despite taking a $13.6 billion hit to its unremitted foreign earnings thanks to new efforts to reform the U.S. tax system, the company said it is pleased with the legislation […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn